Company profile: Chord Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical drug development for rare, life-threatening and severely disabling diseases, advancing lead candidate CRD1 under orphan drug designation for neuromyelitis optica spectrum disorders (NMOSD) and myasthenia gravis (MG).
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Chord Therapeutics
Aeglea BioTherapeutics
HQ: United States
Website
- Description: Provider of clinical-stage enzyme therapies for rare metabolic diseases and investigational monoclonal antibody programs for IBD, including SPY001 targeting α4β7 integrin and SPY002 targeting TL1A, with rational combination studies (SPY120, SPY130, SPY230) and precision immunology approaches using genetic or biomarker-based patient selection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aeglea BioTherapeutics company profile →
True North Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology therapeutics that selectively inhibit the Complement pathway for diseases of high unmet clinical need, featuring lead monoclonal antibody TNT009 targeting the Classical Complement pathway to selectively inhibit downstream phagocytosis, inflammation, and cell lysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full True North Therapeutics company profile →
Vtesse Pharma
HQ: United States
Website
- Description: Provider of rare disease drug development for underserved patients, working collaboratively to advance VTS-270, which has shown promise in pre-clinical and clinical studies as a potential treatment for Niemann-Pick Disease; first spin-out of Cydan Development, Inc., an orphan-drug accelerator.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vtesse Pharma company profile →
Rallybio
HQ: United States
Website
- Description: Provider of biotechnological R&D services developing investigational therapies, including RLYB212 to prevent HPA-1a alloimmunization in expectant mothers at higher risk of FNAIT; RLYB116, a self-delivered C5-targeting antibody mimetic; RLYB114, a C5-targeted Affibody for ophthalmic diseases; RLYB331, a monoclonal antibody targeting MTP-2 for iron overload; and an ENPP1 inhibitor program for hypophosphatasia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rallybio company profile →
Ultragenyx
HQ: United States
Website
- Description: Provider of therapeutics for rare and ultra-rare diseases, including CRYSVITA for XLH, MEPSEVII for MPS VII, and DOJOLVI for LC-FAOD. Develops investigational therapies such as UX143 (setrusumab) for osteogenesis imperfecta and GTX-102 for Angelman syndrome. Offers UltraCare patient support with assistance for insurance coverage, financial support, and access to resources.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ultragenyx company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Chord Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Chord Therapeutics
2.2 - Growth funds investing in similar companies to Chord Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Chord Therapeutics
4.2 - Public trading comparable groups for Chord Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →